H H Bailey

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96
    Howard H Bailey
    University of Wisconsin Madison, Madison, Wisconsin 53792, USA
    Gynecol Oncol 85:464-8. 2002
  2. ncbi request reprint A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, K6 568 CSC, 600 Highland Avenue, Madison, WI 53792 5669, USA
    Cancer Chemother Pharmacol 54:368-76. 2004
  3. ncbi request reprint Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
    H H Bailey
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Natl Cancer Inst 89:1789-96. 1997
  4. ncbi request reprint L-S,R-buthionine sulfoximine: historical development and clinical issues
    H H Bailey
    University of Wisconsin Comprehensive Cancer Center, Department of Medicine, Madison 53792, USA
    Chem Biol Interact 111:239-54. 1998
  5. ncbi request reprint Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:149-57. 2008
  6. pmc Green tea polyphenols for prostate cancer chemoprevention: a translational perspective
    J J Johnson
    University of Wisconsin School of Pharmacy, Division of Pharmacy Practice, 1031 Rennebohm Hall, Madison, WI, USA
    Phytomedicine 17:3-13. 2010
  7. ncbi request reprint Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
    David M Kushner
    Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
    Gynecol Oncol 105:358-64. 2007
  8. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
  9. ncbi request reprint Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, WI 53792, USA
    Cancer Invest 23:13-8. 2005
  10. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009

Collaborators

Detail Information

Publications22

  1. ncbi request reprint A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96
    Howard H Bailey
    University of Wisconsin Madison, Madison, Wisconsin 53792, USA
    Gynecol Oncol 85:464-8. 2002
    ..Perillyl alcohol was administered orally, four times daily, at a dose of 1200 mg/m(2). This was repeated until disease progression or unacceptable toxicity was experienced...
  2. ncbi request reprint A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, K6 568 CSC, 600 Highland Avenue, Madison, WI 53792 5669, USA
    Cancer Chemother Pharmacol 54:368-76. 2004
    ..A phase I study of POH for 14 days out of every 28 days in subjects with advanced malignancies was performed to evaluate dose escalation, toxicity, pharmacokinetics, and effects on TGFbeta and Ras...
  3. ncbi request reprint Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
    H H Bailey
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
    J Natl Cancer Inst 89:1789-96. 1997
    ....
  4. ncbi request reprint L-S,R-buthionine sulfoximine: historical development and clinical issues
    H H Bailey
    University of Wisconsin Comprehensive Cancer Center, Department of Medicine, Madison 53792, USA
    Chem Biol Interact 111:239-54. 1998
    ..Evidence of clinical activity has been observed in patients with alkylating or platinating agent-refractory tumors. Phase II evaluation of CI BSO with L-PAM is in progress...
  5. ncbi request reprint Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue K4 6 CSC, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 62:149-57. 2008
    ..We conducted a phase II multi-institutional study of oral POH administered four times daily in women with advanced treatment-refractory breast cancer...
  6. pmc Green tea polyphenols for prostate cancer chemoprevention: a translational perspective
    J J Johnson
    University of Wisconsin School of Pharmacy, Division of Pharmacy Practice, 1031 Rennebohm Hall, Madison, WI, USA
    Phytomedicine 17:3-13. 2010
    ..The data that has been collected so far suggests that green tea may be a promising agent for PCa chemoprevention and further clinical trials of participants at risk of PCa or early stage PCa are warranted...
  7. ncbi request reprint Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial
    David M Kushner
    Division of Gynecologic Oncology, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, and Regional Cancer Center at Oconomowoc Waukesha Memorial Hospitals, WI, USA
    Gynecol Oncol 105:358-64. 2007
    ..The optimal specific combination has yet to be determined. The current study evaluates weekly docetaxel and carboplatin in this setting...
  8. ncbi request reprint Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
    Howard H Bailey
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer 107:2462-7. 2006
    ....
  9. ncbi request reprint Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, WI 53792, USA
    Cancer Invest 23:13-8. 2005
    ..The response rate appears similar to other reports using different doses and schedules. Myelosuppression appears less with this schedule than with other schedules...
  10. pmc Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
    Steven Attia
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 64:45-51. 2009
    ..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
  11. pmc A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer
    Howard H Bailey
    University of Wisconsin Paul P Carbone Cancer Center, Madison, USA
    Cancer Prev Res (Phila) 3:35-47. 2010
    ..069) in new NMSC that was predominantly due to a marked reduction in new BCC. Based on these data, the potential of DFMO, alone or in combination, to prevent skin cancers should be explored further...
  12. ncbi request reprint Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol
    James P Thomas
    University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, 600 Highland Ave, Madison, WI 53792, USA
    Cancer Chemother Pharmacol 50:465-72. 2002
    ..We conducted a phase I trial and pharmacokinetic study of flavopiridol given as a 72-h continuous intravenous infusion repeated every 2 weeks...
  13. pmc Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M Traynor
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
    Invest New Drugs 29:316-22. 2011
    ..To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors...
  14. ncbi request reprint Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors
    Howard H Bailey
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 13:3623-9. 2007
    ..To assess the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacodynamics, and antitumor activity of continuous weekly-administered paclitaxel and BMS-214662, a novel farnesyl transferase inhibitor...
  15. ncbi request reprint Gemcitabine, Paclitaxel, and piritrexim: a phase I study
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, USA
    Am J Clin Oncol 26:280-4. 2003
    ..The combination of these new antifolates with paclitaxel and gemcitabine appears safe and should be considered for phase II trials in known responsive tumors such as transitional cell carcinomas...
  16. pmc Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study
    J E Chang
    Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI, USA
    Hematol Oncol 27:11-6. 2009
    ..As(2)O(3) and AA in this novel dosing strategy was generally well tolerated but had limited activity in patients with relapsed and refractory lymphoid malignancies...
  17. ncbi request reprint Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
    B S Kahl
    Department of Medicine, University of Wisconsin, Madison, WI, USA
    Ann Oncol 17:1418-23. 2006
    ..There is no standard first line treatment for mantle cell lymphoma...
  18. ncbi request reprint Constitutive and beta-naphthoflavone-induced expression of the human gamma-glutamylcysteine synthetase heavy subunit gene is regulated by a distal antioxidant response element/TRE sequence
    R T Mulcahy
    Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA
    J Biol Chem 272:7445-54. 1997
    ..Collectively the data indicate that the constitutive and beta-NF-induced expression of the human GCS heavy subunit gene is mediated by a distal ARE sequence containing an embedded tetradecanoylphorbol-13-acetate-responsive element...
  19. ncbi request reprint Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125
    Gregory W Allen
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Gynecol Oncol 94:811-3. 2004
    ..A review of the literature is presented and a possible mechanism for CA-125 elevation in diseases other than ovarian cancer is discussed...
  20. ncbi request reprint Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2
    Ellen M Hartenbach
    University of Wisconsin Comprehensive Cancer Center, Gynecologic Oncology Program, Madison 53792, USA
    Genet Test 6:75-8. 2002
    ..In our program, the majority of families counseled were eligible for BRCA1/BRCA2 testing, but only 18% have elected to proceed at this time...
  21. ncbi request reprint Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer
    Glenn Liu
    Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
    Clin Cancer Res 9:4077-83. 2003
    ..Given the cytostatic nature of the drug, the primary study end point was progression-free survival for a minimum of 6 months. The secondary end point was further characterization of drug toxicity...
  22. ncbi request reprint A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study
    Deborah K Armstrong
    John Hopkins Kimmel Cancer Center, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231 1000, USA
    Gynecol Oncol 103:391-6. 2006
    ..The goals of this phase I study were to determine the maximum tolerated dose (MTD) of IP paclitaxel microspheres and the pharmacology of paclitaxel after IP paclitaxel microsphere administration...